| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435326000 | Animal cell, per se, expressing immunoglobulin, antibody, or fragment thereof | 78 |
| 20100021995 | BIOLOGICAL PRODUCTS - There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22. | 01-28-2010 |
| 20080261301 | Antibody Composition-Producing Cell - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 10-23-2008 |
| 20130071921 | ANTIBODIES SPECIFIC FOR DKK-1 AND THEIR USES - The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1 | 03-21-2013 |
| 20100075413 | IMPROVED PROCESS FOR THE CULTURING OF CELLS - The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture. | 03-25-2010 |
| 20090325287 | Methods for Obtaining High Viable Cell Density in Mammalian Cell Culture - Methods for increasing viability in fed batch eukaryotic cell culture are disclosed. | 12-31-2009 |
| 20110287533 | NOVEL LOWERED AFFINITY ANTIBODIES AND USES THEREFOR - The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects. | 11-24-2011 |
| 20090291493 | HUMAN IMMUNODEFICIENCY VIRUS-NEUTRALIZING ANTIBODIES WITH IMPROVED BREADTH AND POTENCY - The present invention provides an antibody to human immunodeficiency virus (HIV) envelope glycoprotein that can recognize one or more strains of HIV, wherein the epitope of HIV recognized by the antibody is inducible, and wherein the antibody binding to the epitope is enhanced by the presence of CD4 and the HIV co-receptor, and related fusion proteins, conjugates, nucleic acids, vectors, host cells, compositions and methods of use to inhibit an infection of a human at risk of becoming infected with HIV, to reduce the severity of an infection of a human infected with HIV, and to treat an infection of a human with HIV. | 11-26-2009 |
| 20090239296 | Compositions and Methods for Modifying Cell Surface Glycans - Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein. | 09-24-2009 |
| 20100136683 | METHODS FOR ISOLATING CELLS BASED ON PRODUCT SECRETION - The invention provides methods for purifying one or more cells based on the level of one or more products secreted by the cells. In one embodiment, the method involves (a) contacting a plurality of cells immobilized in proximity to a capture matrix, the capture matrix capable of localizing a product secreted by one or more of the cells, with an agent that selectively binds to the product, the agent capable of generating a signal detectable as a property of light; (b) illuminating a population of the cells, the population contained in a frame; (c) detecting two or more properties of light directed from the frame, wherein a first property of light identifies substantially all cells of the population, and the second property of light identifies product localized to the capture matrix; (d) locating (i) substantially all cells of the population with reference to the detected first property of light, and (ii) one or more selected cells with reference to the detected second property of light, and (e) irradiating the non-selected cells, wherein each non-selected cell receives a substantially lethal dose of radiation, whereby one or more selected cells having a desired product secretion profile are purified. | 06-03-2010 |
| 20110129916 | MONOCLONAL ANTIBODIES WITH SPECIFICITY FOR FETAL ERYTHROID CELLS - The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The inventive monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell. | 06-02-2011 |
| 20100311160 | Cultures of E1-immortalized cells and processes for culturing the same to increase product yields therefrom - Provided are processes for culturing cells derived from embryonic retinoblast cells immortalized by adenovirus E | 12-09-2010 |
| 20110076763 | NEOPLASM SPECIFIC ANTIBODIES AND USES THEREOF - The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms. | 03-31-2011 |
| 20110027878 | RANDOM HOMOZYGOUS GENE PERTURBATION TO ENHANCE ANTIBODY PRODUCTION - The invention reflects enhanced antibody expression of an antibody of interest by cell lines transformed by random homozygous gene perturbation methods to either increase or decrease the expression pattern of a gene of the cell line other than the antibody of interest. The transformed cell line exhibits specific productivity rates, SPR, for the RHGP transformed cell liens of 1.5 or more, as compared with the antibody expressing cell line parents prior to transformation by RHGP. A knock out or anti-sense construct may be devised to reduce expression of the target gene, a promoter may be inserter to enhance expression of the target gene. The antibodies expressed by the transformed cell lines exhibit the binding properties of their parent cell lines prior to transformation with RHGP, and increase Total Volumetric Production of said antibody by said cells in a given volume. | 02-03-2011 |
| 20110143432 | USE OF EXTRACT OF SELENIUM-ENRICHED YEAST (SE-YE) IN MAMMALIAN CELL CULTURE MEDIA FORMULATIONS - The invention relates to the use of extract of selenium-enriched yeast (Se-YE) as a supplement to the serum-free cell culture media formulations. The cell culture media comprising this supplement are particularly suitable for cultivating mammalian cells and for production of recombinant proteins and monoclonal antibodies. | 06-16-2011 |
| 20100021996 | Genetically Altered Anti-body Producing Cell Lines With Improved Antibody Characteristics - Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. Cells may be selected for expression of activation-induced cytidine deaminase (AID), stimulated to produce AID, or manipulated to express AID for further enhancement of hypermutability. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. | 01-28-2010 |
| 20120315697 | Cell Culture Media Containing Combinations of Proteins - The present invention relates to cell culture media containing combinations of proteins, as well as methods of making the cell culture media, and methods of using the cell culture media to improve growth characteristics of cultured cells. | 12-13-2012 |
| 20110003382 | USE OF CORTICOSTERONE FOR INCREASING EGG ANTIBODY - Methods for increasing antigen-specific egg yolk antibody titer and eggs having increased antigen-specific egg yolk antibody titer are disclosed. More specifically, the method for increasing antibody titer may include the steps of: administering to an egg-laying animal a corticosteroid; and then, exposing the animal to an immunogenic dose of the antigen. | 01-06-2011 |
| 20100203631 | ANTIBODIES TO ALPHA-SYNUCLEIN - The invention provides methods for detecting alpha-synuclein. The invention also identifies preferred epitopes of alpha synuclein for use in such detection, and provides antibodies specifically binding to such epitopes. | 08-12-2010 |
| 20100203630 | IN VITRO HUMAN B LYMPHOPOIESIS CULTURE SYSTEM - The present disclosure relates to systems, methods and compositions for the generation of antibody-producing B cells in vitro. Some embodiments are related to an in vitro system for generating antibody-producing B cells from hematopoietic stem/progenitor cells (HSPCs). | 08-12-2010 |
| 20110275147 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
| 20120252117 | OPTIMIZED MESSENGER RNA - The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons. | 10-04-2012 |
| 435328000 | Immunoglobulin or antibody is chimeric, mutated, or a recombined hybrid (e.g., bifunctional, bispecific, rodent-human chimeric, single chain, rFv, immunoglobuin fusion protein, etc.) | 21 |
| 20090280563 | METHOD FOR PRODUCTION OF ANTIGEN-SPECIFIC HYBRIDOMA USING ARTIFICIAL LYMPH NODE WITH GOOD EFFICIENCY - Provided herein is a method for efficiently producing a hybridoma producing a specific antibody using an artificial lymph node. | 11-12-2009 |
| 20090263894 | ANTIBODIES THAT BIND TO MAMMALIAN NGAL AND USES THEREOF - The present invention relates to antibodies specific for glycosylated mammalian NGAL, and to methods of making and using such antibodies. | 10-22-2009 |
| 20090155897 | GLYCOPROTEIN VI FUSION PROTEINS - The present invention relates to Glycoprotein VI (GPVI) fusion proteins (GPVI-fusion proteins) comprising a tag like myc, GST, HA, FLAG, STREP but preferably a Immunoglobulin molecule (Ig), more preferably a Fc portion of said Ig and a protein or oligopeptide having the biological activity of GPVI (GPVI-like protein) which is binding to collagen and their use in methods and kits for the screening of potential agonists or antagonists for GPVI-collagen and/or platelet-collagen interaction is disclosed. | 06-18-2009 |
| 20100041136 | Connective Tissue Growth Factor-2 - The present invention relates to a human CTGF-2 polypeptide and DNA (RNA) encoding such polypeptide. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist/inhibitors against such polypeptide. Also provided are methods of using the polypeptide therapeutically for enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed. | 02-18-2010 |
| 20120164726 | BIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to a host cell for use in the expression of a novel domain exchanged, bivalent, bispecific antibody. | 06-28-2012 |
| 20130065299 | ACTRIIB-FC POLYNUCLEOTIDES, POLYPEPTIDES, AND COMPOSITIONS - In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand. | 03-14-2013 |
| 20110111495 | CONCENTRATED MEDIUM AND ITS USAGE - This invention discloses a kind of concentrated medium for large-scale culture of Chinese Hamster Ovary cell. The said medium comprises basic medium and high dose additives. This invention also discloses the method of adding the described concentrated medium in large-scale fed-batch culture of CHO cells. | 05-12-2011 |
| 20100221823 | METHOD FOR CULTURING MAMMALIAN CELLS TO IMPROVE RECOMBINANT PROTEIN PRODUCTION - The present invention relates to methods for mammalian cell culture, wherein the methods make use of media containing polyamines, such as putrescine, spermidine and spermine. | 09-02-2010 |
| 20110236968 | HUMANIZED ANTIBODIES AGAINST MONOCYTE CHEMOTACTIC PROTEINS - The invention provides humanized antibodies that bind to a plurality of β-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity. | 09-29-2011 |
| 20100221822 | Humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria - The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics. | 09-02-2010 |
| 20110250681 | Fc Variants with Optimized Properties - The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties. | 10-13-2011 |
| 20120015436 | DEGRADED TPO AGONIST ANTIBODY - The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc. | 01-19-2012 |
| 20120015435 | PCSK9 ANTAGONISTS - The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia. | 01-19-2012 |
| 20110059524 | HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF - A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient. | 03-10-2011 |
| 20120238013 | FUSION PARTNER FOR PRODUCTION OF MONOCLONAL RABBIT ANTIBODIES - The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications. | 09-20-2012 |
| 20120122206 | Glycosylation Engineering of Antibodies for Improving Antibody-Dependent Cellular Cytotoxicity - The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that includes a region equivalent to the Fc region of an immunoglobulin, with enhanced Fc-mediated cellular cytotoxicity. | 05-17-2012 |
| 20090061511 | GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS - Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases. | 03-05-2009 |
| 20120088299 | Mammalian Cell Lines for Increasing Longevity and Protein Yield from a Cell Culture - Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hamiones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells. | 04-12-2012 |
| 20130143316 | NUCLEIC ACIDS MOLECULE ENCODING THE POLYPEPTIDE FOR TREATING VIRUS-INDUCED CANCER - The present invention relates to nucleic acid molecules encoding the polypeptides that are capable of killing tumor cells. The molecules comprise a targeting agent covalently attached to a channel-forming moiety. In a preferred embodiment, the channel-forming moiety comprises a colicin and the targeting agent is a reconstructed antibody mimetic derived from monoclone antibody against Epstein-Barr virus gp350/220. | 06-06-2013 |
| 20130102072 | SUPPRESSION OF B-CELL APOPTOSIS IN TRANSGENIC ANIMALS EXPRESSING HUMANIZED IMMUNOGLOBULIN - The invention provides a novel approach to increase immunoglobulin expression in non-human transgenic animals. For instance, the invention provides a method to increase humanized immunoglobulin production in animals genetically engineered to express one or several human or humanized immunoglobulin transloci. This can be done by overexpressing the apoptosis inhibitor, i.e. a rabbit bcl-2, whose expression is driven by a B-cell specific promoter specifically in the B-cell of the animal, thereby enhancing the survival of B-cells. This invention further relates to a method for selectively enhancing the survival of exogenous B-cells, that is B-cells expressing any immunoglobulin transgene locus, over the survival of endogenous B-cells that do not express the transgene locus. Selectivity is achieved by expressing the apoptosis-inhibitor only within exogenous B-cells, that is, by coupling exogenous immunoglobulin expression with apoptosis inhibitor expression. This latter method allows for increased expression and production of the transgene encoded product(s) over the endogenously produced immunoglobulin of the transgenic animal. The invention also provides a novel apoptosis-inhibitor, rabbit bcl-2. | 04-25-2013 |
| 20130130372 | ENHANCED EXPRESSION AND STABILITY REGIONS - Expression-enhancing nucleotide sequences for expression in eukaryotic systems are provided that allow for enhanced and stable expression of recombinant proteins in eukaryotic cells. Enhanced expression and stability regions (EESYRs) are provided for expression of a gene of interest in a eukaryotic cell. Chromosomal loci, sequences, and vectors are provided for enhanced and stable expression of genes in eukaryotic cells. | 05-23-2013 |
| 435330000 | Immunoglobulin or antibody binds an expression product of a cancer related gene or fragment thereof (e.g., oncogene, proto-oncogene, etc.) | 2 |
| 20090170191 | 84P2A9: A PROSTATE AND TESTIS SPECIFIC PROTEIN HIGHLY EXPRESSED IN PROSTATE CANCER - A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response. | 07-02-2009 |
| 20090162931 | RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERS - The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids. | 06-25-2009 |
| 435331000 | Immunoglobulin or antibody binds a specifically identified amino acid sequence | 13 |
| 20090042285 | Antibodies at T cell receptor mimics, methods of production and uses thereof - The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest. An effective amount of the immunogen is then administered to a host for eliciting an immune response, and serum collected from the host is assayed to determine if desired antibodies that recognize a three-dimensional presentation of the peptide in the binding groove of the MHC molecule are being produced. The desired antibodies can differentiate the peptide/MHC complex from the MHC molecule alone, the peptide alone, and a complex of MHC and irrelevant peptide. Finally, the desired antibodies are isolated. | 02-12-2009 |
| 20130071922 | Anti-C5 Alpha Antibodies - The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system. | 03-21-2013 |
| 20090011499 | Antibodies that bind LDCAM - The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides. | 01-08-2009 |
| 20120107928 | Antibody Inhibitors of GDF-8 and Uses Thereof - The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism. | 05-03-2012 |
| 20100136684 | Natural IgM Antibodies - The invention provides natural IgM antibodies that may be used to induce inflammatory diseases or disorders such as ischemia-reperfusion injury to create animal models of such inflammatory diseases or disorders. | 06-03-2010 |
| 20090137036 | TWEAK RECEPTOR - The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue. | 05-28-2009 |
| 20100015703 | ANTIBODY TO MAMMALIAN CYTOKINE-LIKE POLYPEPTIDE-10 - A mammalian cytokine-like polypeptide, called Mammalian Cytokine-like polypeptide-10, (Zcyto10), polynucleotides encoding the same, antibodies which specifically bind to the polypeptide, and anti-idiotypic antibodies which bind to the antibodies. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets. | 01-21-2010 |
| 20100279399 | Human Cancer Stem Cell Culture Compositions Comprising ErbB2 Variants and Methods of Use - The present invention provides compositions and methods for the culture and maintenance of cancer stem cells. More particularly, the present invention provides the identification of cancer stem cell specific markers and methods of recognizing the same for the detection of tumors, for facilitating the prognosis of a patient with a tumor, and for the treatment of various cancers. The invention also provides antibodies that specifically recognize the disulfide linked Erbb2Δ16 homodimer, an Erbb2Δ16/Erbb3 heterodimer, or post-translational modifications of Erbb2 that are specific to Erbb2 of variant hESCs, in addition, the invention provides a modified defined media useful in the absence of a feeder layer and in the absence of serum or serum replacement, that comprises a basal salt nutrient solution, bFGF, IGF-I, and Activin A, and wherein the composition does not comprise heregulin. The invention further relates to the use of an Erbb2 variant isoform to generate robust cell cultures that are independent of heregulin. | 11-04-2010 |
| 20120034690 | Cell lines producing blocking antibodies to human RANKL - Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL. | 02-09-2012 |
| 20110003383 | ANTIBODIES TO HT5GJ57 - The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins. | 01-06-2011 |
| 20100129905 | MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - Purified genes encoding cytokines from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided. | 05-27-2010 |
| 20080233638 | PAAD domain-containing polypeptides, encoding nucleic acids, and methods of use - The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NACHT domains and ARED domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NFκB activity, or modulate an activity of a NACHT domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NFκB transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell. | 09-25-2008 |
| 20080227194 | Canine pancreatic lipase - Isolated nucleic acid molecules having a nucleotide sequence encoding canine pancreatic lipase polypeptides, allelic variants and fragments thereof. Vectors and host cells containing the polynucleotide sequences and methods for expressing the polypeptides. Monoclonal antibodies that specifically binds to the canine pancreatic lipase polypeptides. Cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of canine pancreatic lipase in a biological sample. The methods include using the monoclonal antibodies to specifically bind to canine pancreatic lipase polypeptides. The method includes using standards of recombinant canine pancreatic lipase. Devices and kits for performing methods for detecting canine pancreatic lipase in biological samples. | 09-18-2008 |
| 435332000 | Immunoglobulin or antibody binds a microorganism or normal or mutant component or product thereof (e.g., animal cell, cell surface antigen, secretory product, etc.) | 20 |
| 20120225478 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE - The present invention relates to antibody molecules capable of specifically recognizing two regions of the β-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention. | 09-06-2012 |
| 20110223658 | MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP) | 09-15-2011 |
| 20090197330 | ANTI-CD20 MONOCLONAL ANTIBODY - Disclosed is a monoclonal antibody capable of inducing a specific biological reaction through the binding of the monoclonal antibody to a CD20 antigen on the surface of a cell. A monoclonal antibody having a high binding affinity to an extracellular epitope of a CD20 antigen and also having biological activities including a cell growth inhibitory activity is cloned. The monoclonal antibody is chimerized or humanized to develop a therapeutic agent for a disease in which B cells are involved. | 08-06-2009 |
| 20120329149 | HUMANIZED ANTIBODY - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 12-27-2012 |
| 435334000 | Binds a receptor (e.g., transferrin receptor, Fc receptor, dihydropyridine receptor, IL-2 receptor, etc.) | 8 |
| 20130078717 | BINDING MEMBERS-513 - This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K | 03-28-2013 |
| 20090047735 | Antibodies Against Human G-Protein Chemokine Receptor (CCR5) HDGNR10 - The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies. | 02-19-2009 |
| 20110281348 | AGONIST ANTI-TRKC ANTIBODIES AND METHODS USING SAME - The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy. | 11-17-2011 |
| 20110053265 | Cell Culture Performance with Betaine - This invention relates generally to the field of cell culture. More particularly, the invention relates to improving viability of recombinant cell cultures and the yields of secreted polypeptides therefrom by the addition of betaine to the tissue culture medium. | 03-03-2011 |
| 20100081195 | Modified Host Cells and Uses Thereof - The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value. | 04-01-2010 |
| 20100190247 | Methods of Generating Variant Proteins with Increased Host String Content - The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. | 07-29-2010 |
| 20110236969 | METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING CONTENT AND COMPOSITIONS THEREOF - The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. | 09-29-2011 |
| 20130023047 | Nucleic Acids Encoding Humanized Anti-CD40 Antibodies - Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen. | 01-24-2013 |
| 435335000 | Binds a lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, intercellular mediator specific for a hematopoietic cell (e.g., interleukin, interferon, erythropoietin, etc.) | 3 |
| 20130071923 | HUMAN GM-CSF ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes. | 03-21-2013 |
| 20120202285 | ANTIBODIES TO IL-6 AND THEIR USES - Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions. | 08-09-2012 |
| 20110091968 | MONOCLONAL ANTIBODY SPECIFIC TO BOTH HUMAN INTERFERON-ALPHA SUBTYPE ALPHA 8 AND ITS MUTANT PROTEINS - The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFNα8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFNα8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8. The present invention solves the above objects by providing a monoclonal antibody specific to IFNα8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFNα8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFNα8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8, which contains the monoclonal antibody as an effective ingredient. | 04-21-2011 |
| 435336000 | Binds a hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, intragonadal regulatory protein, Mullerian inhibiting substance, inhibin, epidermal growth factor, nerve growth factor, dopamine, norepinephrine, etc.) | 1 |
| 20120142091 | Antibodies Against Human Angiopoietin 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 06-07-2012 |
| 435339000 | Binds a virus or component or product thereof (e.g., virus associated antigen, etc.) | 1 |
| 20100279400 | DIAGNOSTIC TEST FOR WEST NILE VIRUS - The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV. The present invention also provides a rapid, sensitive, and consistent method for the specific detection of DENV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-DENV antibodies but do not cross-react with antibodies against other flaviviruses such as JEV, SLEV, or WNV. Further, the DENV NS5 antigens are serospecific and do not cross react with antibodies to other DENV strains. Thus, the method of the present invention provides a manner by which to discriminate infections by each DENV strain. Further, diagnostic kits for carrying out the methods are provided. The methods and kits for carrying out the methods of the invention are rapid and require as little as 10 minutes to detect a result. The invention also provides monoclonal antibodies against WNV NS5 and DENV NS5 antigen and their use in detecting WNV and DENV infections in a biological sample. | 11-04-2010 |
| 435340000 | Binds a bacterium or similar microorganism or component or product thereof (e.g., Streptococcus, Legionella, Mycoplasma, bacterium associated antigen, exotoxin, etc.) | 3 |
| 20120196359 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-02-2012 |
| 20120208270 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-16-2012 |
| 20110275148 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
| 435345000 | Immunoglobulin or antibody binds a drug, hapten, hapten-carrier complex, or specifically identified chemical structure (e.g., theophylline, digoxin, etc.) | 1 |
| 20090221066 | Anti-Methylated Dna Antibody and Method for Production Thereof - The present invention provides a method of preparing an anti-methylated DNA antibody, comprising a step of administering to an animal an oligodeoxyribonucleotide containing a methylated cytosine(s) and an oligodeoxyribonucleotide containing no methylated cytosine. The antibody prepared by this method is capable of detecting a DNA containing a methylated cytosine(s) in a state close to the state of a biological component. | 09-03-2009 |
